-
Innovation Ranking
NewInnovation Ranking – GF Securities Co Ltd
GF Securities Co Ltd (GF Securities) is a provider of investment banking and capital market services. Its portfolio of business activities includes investment banking, wealth management, trading and institutional client services, and investment management. Investment banking services comprise equity financing, debt financing, financial consulting, and merges and acquisition advisory. It provides investment management services such as asset management, fund management, private equity investments, and alternative investment services. GF Securities provides brokerage services include trading, leasing, and custodian services to institutional...
-
Company Insights
Innovation and Patenting activity of GF Securities Co Ltd Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of GF Securities Co Ltd Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GFH-018 in Cervical Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GFH-018 in Cervical Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GFH-018 in Cervical Cancer Drug Details: GF-101 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GFH-018 in Metastatic Hepatocellular Carcinoma (HCC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GFH-018 in Metastatic Hepatocellular Carcinoma (HCC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GFH-018 in Metastatic Hepatocellular Carcinoma (HCC) Drug Details: GF-101...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GFH-018 in Metastatic Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GFH-018 in Metastatic Pancreatic Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GFH-018 in Metastatic Pancreatic Cancer Drug Details: GF-101 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GFH-018 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GFH-018 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GFH-018 in Solid Tumor Drug Details: GF-101 is under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – GFH-018 in Bile Duct Cancer (Cholangiocarcinoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GFH-018 in Bile Duct Cancer (Cholangiocarcinoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GFH-018 in Bile Duct Cancer (Cholangiocarcinoma) Drug Details: GF-101 is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – GFH-018 in Gallbladder Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GFH-018 in Gallbladder Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GFH-018 in Gallbladder Cancer Drug Details: GF-101 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GFH-018 in Esophageal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GFH-018 in Esophageal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GFH-018 in Esophageal Cancer Drug Details: GF-101 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GFH-018 in Nasopharyngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GFH-018 in Nasopharyngeal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GFH-018 in Nasopharyngeal Cancer Drug Details: GF-101 is under development for...